Latest Panitumumab Stories
IRVING, Texas and PHOENIX, June 24 /PRNewswire/ -- Caris Diagnostics (Caris Dx), a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing, announced that it is now offering KRAS mutation analysis, designed to provide information on which colon cancer patients are most likely to respond to cetuximab (Erbitux) co-marketed by ImClone and Bristol-Myers Squibb or panitumumab (Vectibix)...
Merck KGaA has submitted an application to the European Medicines Agency to broaden the use of the targeted therapy Erbitux to include first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
LOS ANGELES (Reuters) - Biotechnology company Amgen Inc. said on Monday that the U.S. Food and Drug Administration has agreed to a "priority review" of the company's application for experimental drug panitumumab as a treatment for colon cancer.
Using combinations of "smart bomb" cancer drugs that target specific proteins and avoid the indiscriminate cell destruction of chemotherapy may be the wave of the future for cancer patients, experts say.
LOS ANGELES (Reuters) - Amgen Inc. said on Saturday that testing tumors for the protein that its experimental colon cancer drug panitumumab is designed to target is not an accurate measure of whether a patient will respond to the treatment.
By Toni Clarke ATLANTA (Reuters) - Using combinations of "smart bomb" cancer drugs that target specific proteins and avoid the indiscriminate cell destruction of chemotherapy may be the wave of the future for cancer patients, experts say.
By Megan Rauscher WASHINGTON (Reuters Health) - A
CHICAGO (Reuters) - Amgen Inc. and Abgenix Inc. said on Thursday a late-stage study found its experimental drug panitumumab helped slow tumor progression in patients with advanced colon cancer who had failed multiple other therapies.
Scientists have uncovered new information about a specific mechanism involved in the biology of malignant human tumor cells. The findings, published in the June issue of Cancer Cell, significantly advance knowledge about epidermal growth factor receptor (EGFR).
- Large; stout; burly.